NEW YORK , April 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or the "Company") (NASDAQ: PEPG). Such investors are advised to contact...
NEW YORK , April 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or the "Company") (NASDAQ: PEPG). Such investors are advised to contact...
NEW YORK , April 2, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or the "Company") (NASDAQ: PEPG). Such investors are advised to contact...
NEW YORK , April 2, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or the "Company") (NASDAQ: PEPG). Such investors are advised to contact...
– PGN-EDODM1 was generally well-tolerated with all adverse events mild or moderate and no serious adverse events reported – – Mean splicing correction of 7.3% observed...
NEW YORK , March 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or the "Company") (NASDAQ: PEPG). Such investors are advised to contact...
NEW YORK , March 19, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or the "Company") (NASDAQ: PEPG). Such investors are advised to contact...
NEW YORK , March 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or the "Company") (NASDAQ: PEPG). Such investors are advised to contact...
– FREEDOM2-DM1 5 mg/kg cohort data expected in Q1 2026 – – Patient dosing in the FREEDOM2 10 mg/kg cohort is proceeding in Canada and the UK, with data expected...
- U.S. FDA places FREEDOM2 trial on partial clinical hold related to preclinical pharmacology and toxicology - - Received regulatory clearance to initiate FREEDOM2 in South Korea, Australia, and...